CIPOLLO Byos license

The contract pertains to a software license for CIPOLLO Byos, which is specialized in mass spectrometry data analysis. It is a forecasted opportunity announced by the Food and Drug Administration (FDA) on March 11, 2026, linked to the NAICS code 511210, indicating it involves software publishing services. The contract aims to procure licensing rights for the CIPOLLO Byos software to support the FDA’s analytical needs in processing mass spectrometry data. Key contacts include the CBER Acquisition Liaison, reachable via email at cberacquisitions@fda.hhs.gov, while the contracting officer position is yet to be assigned. Specific details about the physical location for contract performance are not provided. The announcement serves as a preliminary notice rather than an active solicitation, with further information and updates expected through the FDA’s industry forecast platform.